bio overview
DESCRIPTION
BIO Overview. BIO Fact Sheet. Founded: 1993 Tax Status: Non-profit trade association Pres & CEO:James C. Greenwood Chairman: Steve Sherwin Chairman & CEO Cell Genesys Headquarters: Washington, DC Staff: 160 Members: Approximately 1,200 organizations. BIO Mission. - PowerPoint PPT PresentationTRANSCRIPT
BIO Overview
BIO Fact Sheet
• Founded: 1993• Tax Status: Non-profit trade association• Pres & CEO: James C. Greenwood• Chairman: Steve Sherwin
Chairman & CEOCell Genesys
• Headquarters: Washington, DC• Staff: 160• Members: Approximately 1,200 organizations
2
BIO Mission
3
• Create a positive environment that promotes continued biotech innovation
• Policy• Legislative• Regulatory• Legal
• BIO represents more than just an Industry
• BIO represents Innovation
• Business• Access to capital• Partnering
• Public Opinion• Communications• Branding campaign
Health:88%
Food & Ag:4%
Academic/ Non-Profit:
16%
State/ International
Affiliates:6%
Service Providers:
11%
R&D Organizations:
67%
Membership Breakdown
~800 R&D Members
Less than $25M:
90%
$25M - $1B:5%
$1B and Greater:
5%
Industrial & Environmental:
8%
4
Revenue
Approximately 1,200 Members
September 2009
Market Focus
5
6
Unique Trade Association
• Diverse membership – “Big Tent”• Health, Food & Agriculture, Industrial & Environmental• Pre-emerging – Fortune 500• International membership now greater than 20%
• World-class advocacy team• Federal & state government relations• International initiative• Policy• Public relations
• Coordinated lobbying effort• BIO • Member companies• State affiliates• Coalitions
7
Unique Trade Association
• State affiliate network• 45 affiliates in 42 states• Coordinated state-level advocacy in all 42 states• Membership in BIO provides a voice in affiliate states
• Coalition building• Patient groups• Academia• Other industry groups
• Beyond traditional services• Business Solutions program for cost savings• Investor & Innovator conferences among best in the industry
8
9
2009 Policy Issues
• Biosimilars• Comparative Effectiveness• Reimbursement: patient access• Improving the performance of FDA• Intellectual property protection• International advocacy• Vaccine innovation & pandemic and bio-defense
preparedness• Research tools & molecular diagnostics
Innovator & Investor Conferences
Investor:
• BIO CEO & Investor Conference
• BIO National Venture Conference
• BIO Investor Forum
Innovator:
• BIO-Asia
• BIO-Europe Spring
• BIO-Windhover &
Windhover PSO
• The Business Forum at the BIO International Convention
• BIO-India
• BIO-Europe
10
• One-on-one partnering meetings
• Scheduled via BIO’s proprietary online partnering system
• Company presentations
• Therapeutic and business expert panels
• Networking receptions
• Invitation-only events
Innovator Conference Elements
11
12
Communications
• Campaign Goals
• Advance policy goals• Build, organize, and have the potential to mobilize a
network of biotech advocates and brand ambassadors
• Increase awareness & favorable opinion of biotechnology• Generate positive awareness among elites and those
who influence opinion and policy
Cooperation with China
• BIO China 2010– Format
• Two day event bringing together biotechnology and pharmaceutical companies from the US, Europe and Asia.
• Company presentations, partnering (similar to the Business Forum at the BIO International Convention), and tracks on timely business development and policy topics.
13
Cooperation with China
• BIO China 2010– Attendees
• Chinese biotech firms conducting R&D that seek to meet potential partners.
• International pharmaceutical and biotech companies that seek to partner with Chinese based R&D companies or to out-license their technologies.
• China based service providers.• Innovative biotech companies that seek partners or service
providers.
14
Cooperation with China
• Scientific American Worldview Scorecard– Launched at BIO 2009.– Analysis and ranking of biotech environment in countries across
the globe.– Special look at regulatory, IP, education, infrastructure.– Focus on China in 2010.
• Government Dialogues– U.S.-China Joint Commission on Commerce and Trade– BIO-SFDA Roundtables
15
16